Nkarta Inc
6000 Shoreline Court
Suite 102
South San Francisco
CA
94080
United States
Tel: 415528-3392
Website: https://www.nkartatx.com/
Email: info@nkartatx.com
54 articles with Nkarta Inc
-
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
8/11/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2022.
-
Nkarta Announces Key Senior Leadership Team Appointments
7/25/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA, to Chief Administrative Officer.
-
Nkarta to Participate at Upcoming Investor Conference - May 31, 2022
5/31/2022
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at an upcoming investor conference:
-
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
5/16/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of David R. Shook, MD, as Vice President, Clinical Development.
-
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
5/12/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares - Apr 28, 2022
4/28/2022
Nkarta, Inc. announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share, and the exercise in full by the underwriters of their option to purchase an additional 2,000,000 shares of common stock.
-
Nkarta Announces Pricing of Upsized Public Offering of Common Stock - Apr 26, 2022
4/26/2022
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share.
-
Nkarta announced that two of its therapies have shown complete remission in patients with blood cancer. These results are the latest development in the treatment of difficult-to-treat blood cancers.
-
Nkarta Announces Proposed Public Offering of Common Stock - Apr 25, 2022
4/25/2022
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of its common stock.
-
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
4/25/2022
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies.
-
Nkarta to Participate at Upcoming Investor Conference - Apr 08, 2022
4/8/2022
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at an upcoming investor conference.
-
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
4/8/2022
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.
-
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
3/29/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors.
-
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
3/17/2022
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
3/8/2022
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022.
-
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
-
Nkarta to Participate at Upcoming Investor Conferences - Feb 10, 2022
2/10/2022
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences,
-
Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...
-
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
12/16/2021
Nkarta, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML).